Globalink Investment Inc. (NASDAQ:GLLIW) saw a 581.82% increase, possibly due to speculative activities or news of potential business combinations.Cambium Networks Corporation (NASDAQ:CMBM) experienced a 331.65% rise after integrating its solutions with Starlink, indicating strong growth prospects.Purple Biotech Ltd. (NASDAQ:PPBT) and Ernexa Therapeutics Inc. (NASDAQ:ERNA) both reported significant stock price increases due to advancements in their clinical trials and strategic partnerships, highlighting th ...

CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

Not for distribution by US newswire or in United States NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company intends to complete a non-brokered private placement on a commercially reasonable efforts basis (the "Offering") of up to 2,456,140 units ("Units") of the Company at a price of $0.1425 per Unit to raise gross proceeds of up to $350,000. Each Unit will consist of one common share of the Company ("Sha ...

VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2025 after market close on Wednesday, November 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, fin ...

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45’s addressable Group 2 PH patient population to PH‑HFrEFCompany to host webcast today, October 29th at 4:30 p.m. ET WATE ...

Investors might want to bet on Zymeworks Inc. (ZYME) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C. Wainwright reaffirmed its Buy rating and $50 price target on Assembly Biosciences (NASDAQ:ASMB) following the company’s presentation of interim data for ABI-5366, a long-acting oral treatment for recurrent genital herpes. H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data Source:unsplash Presented data showed strong antiviral activity, favo ...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for 22.4 million shares. The company raised $31 million in gross proceeds from the offering. Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase Investors who exercised the warrants, issued in March and August of last year, are poised to receive new register ...